EA201890507A1 - Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv - Google Patents

Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv

Info

Publication number
EA201890507A1
EA201890507A1 EA201890507A EA201890507A EA201890507A1 EA 201890507 A1 EA201890507 A1 EA 201890507A1 EA 201890507 A EA201890507 A EA 201890507A EA 201890507 A EA201890507 A EA 201890507A EA 201890507 A1 EA201890507 A1 EA 201890507A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
hcv
ribavirin
patients
combination
Prior art date
Application number
EA201890507A
Other languages
English (en)
Russian (ru)
Inventor
Барри М. Бернстейн
Сандип ДУТТА
Вэй ЛЮ
Томас Дж. Подсадеки
Эндрю Л. Кэмпбелл
Раджив М. Менон
Чих-Вэй Лин
Тяньли Ван
Валид М. Авни
Original Assignee
Эббви Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201890507(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эббви Инк. filed Critical Эббви Инк.
Publication of EA201890507A1 publication Critical patent/EA201890507A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201890507A 2013-03-14 2014-03-14 Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv EA201890507A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
EA201890507A1 true EA201890507A1 (ru) 2018-07-31

Family

ID=50771575

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201890507A EA201890507A1 (ru) 2013-03-14 2014-03-14 Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
EA201591701A EA030482B1 (ru) 2013-03-14 2014-03-14 Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201591701A EA030482B1 (ru) 2013-03-14 2014-03-14 Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv

Country Status (28)

Country Link
US (1) US20140274934A1 (enExample)
EP (4) EP2968302B9 (enExample)
JP (3) JP6563894B2 (enExample)
KR (2) KR20180045055A (enExample)
CN (3) CN105007921B (enExample)
AU (3) AU2014239322B2 (enExample)
BR (1) BR112015020918A2 (enExample)
CA (1) CA2901818C (enExample)
CY (1) CY1121474T1 (enExample)
DK (1) DK2968302T3 (enExample)
EA (2) EA201890507A1 (enExample)
ES (1) ES2654109T3 (enExample)
HK (1) HK1255257A1 (enExample)
HR (1) HRP20171898T1 (enExample)
HU (1) HUE036069T2 (enExample)
IL (2) IL240445B (enExample)
LT (1) LT2968302T (enExample)
MX (1) MX2015012536A (enExample)
NO (1) NO3090119T3 (enExample)
PL (1) PL2968302T4 (enExample)
PT (1) PT2968302T (enExample)
RS (1) RS56735B1 (enExample)
SG (2) SG11201507361YA (enExample)
SI (1) SI2968302T1 (enExample)
SM (1) SMT201800017T1 (enExample)
TW (2) TW202002979A (enExample)
WO (1) WO2014152635A1 (enExample)
ZA (1) ZA201705080B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202002979A (zh) 2013-03-14 2020-01-16 美商艾伯維有限公司 治療hcv的方法
WO2015153792A1 (en) * 2014-04-02 2015-10-08 Abbvie Inc. Methods for treating hcv
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015061742A2 (en) * 2013-10-25 2015-04-30 Abbvie, Inc. Methods for treating hcv
EP3082808A1 (en) * 2013-12-19 2016-10-26 AbbVie Inc. Methods for treating liver transplant recipients
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
EP4303760A1 (en) 2016-01-08 2024-01-10 Entrust Corporation Card printing mechanism with card return path
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
MA46292A (fr) * 2016-09-23 2019-07-31 Abbvie Inc Réglage de dose
JP2018131439A (ja) * 2017-02-14 2018-08-23 アッヴィ・インコーポレイテッド Ｈｃｖを処置する方法
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
CN112351799A (zh) * 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009256623A1 (en) * 2008-06-10 2009-12-17 Janssen Pharmaceutica Nv Telaprevir dosing regimen
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
DK2368890T3 (da) * 2009-06-11 2013-07-22 Abbvie Bahamas Ltd Hepatitis C-virusinhibitorer
SG188618A1 (en) * 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
TW202002979A (zh) 2013-03-14 2020-01-16 美商艾伯維有限公司 治療hcv的方法

Also Published As

Publication number Publication date
HUE036069T2 (hu) 2018-06-28
PT2968302T (pt) 2018-01-03
TWI678205B (zh) 2019-12-01
WO2014152635A1 (en) 2014-09-25
IL240445B (en) 2019-07-31
RS56735B1 (sr) 2018-03-30
HK1255257A1 (en) 2019-08-09
CY1121474T1 (el) 2020-05-29
CN109908353A (zh) 2019-06-21
EP3733180A1 (en) 2020-11-04
IL267927A (en) 2019-09-26
JP6563894B2 (ja) 2019-08-21
AU2020201656A1 (en) 2020-03-26
KR20180045055A (ko) 2018-05-03
JP2019167347A (ja) 2019-10-03
TW202002979A (zh) 2020-01-16
EA030482B1 (ru) 2018-08-31
ES2654109T3 (es) 2018-02-12
EP2968302B9 (en) 2019-02-13
CN105007921B (zh) 2018-12-11
CN105007921A (zh) 2015-10-28
EA201591701A1 (ru) 2016-02-29
KR20150129035A (ko) 2015-11-18
KR101853605B1 (ko) 2018-05-03
PL2968302T3 (pl) 2018-04-30
PL2968302T4 (pl) 2018-04-30
LT2968302T (lt) 2017-12-27
SMT201800017T1 (it) 2018-03-08
WO2014152635A9 (en) 2014-12-11
HK1213191A1 (en) 2016-06-30
EP2968302A1 (en) 2016-01-20
IL240445A0 (en) 2015-09-24
US20140274934A1 (en) 2014-09-18
SG10201709840UA (en) 2018-01-30
EP2968302B1 (en) 2017-09-06
ZA201705080B (en) 2019-02-27
CA2901818C (en) 2021-05-04
JP2016513703A (ja) 2016-05-16
SI2968302T1 (en) 2018-04-30
EP3318258B1 (en) 2020-05-13
EP3318258A1 (en) 2018-05-09
JP2019214585A (ja) 2019-12-19
AU2018202581A1 (en) 2018-05-10
MX2015012536A (es) 2016-01-12
SG11201507361YA (en) 2015-10-29
HRP20171898T1 (hr) 2018-04-06
DK2968302T3 (en) 2017-12-18
AU2018202581B2 (en) 2019-12-05
AU2014239322B2 (en) 2018-04-05
AU2014239322A1 (en) 2015-08-27
CN108187056A (zh) 2018-06-22
EP3915559A1 (en) 2021-12-01
BR112015020918A2 (pt) 2017-07-18
NO3090119T3 (enExample) 2018-03-31
CA2901818A1 (en) 2014-09-25
TW201505633A (zh) 2015-02-16

Similar Documents

Publication Publication Date Title
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
EA201591702A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
PH12018550201A1 (en) Hepatitis b antiviral agents
MX2024010140A (es) Nuevos metodos.
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
PH12018550148A1 (en) Hepatitis b antiviral agents
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
PH12018550150B1 (en) Elimination of hepatitis b virus with antiviral agents
EA201490254A1 (ru) Комбинированное лечение гепатита с
UY37998A (es) Agentes antivirales contra la hepatitis b
MX389088B (es) Métodos para tratar el vhc.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
IN2013CH05288A (enExample)
EA202090412A1 (ru) Способы лечения вгс
MX2018001905A (es) Metodos para el tratamiento del virus de hepatitis c (vhc).
WO2014122537A3 (en) Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
EA201892004A1 (ru) Противовирусные средства для лечения гепатита b
NZ631789A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
EA201892732A1 (ru) Противовирусные средства для лечения гепатита в
ES2572355A2 (es) Combinacion de aad para uso en el tratamiento del vhc
RU2014104644A (ru) Способ повышения эффективности лечения коров, больных острым гнойно-катаральным эндометритом
TN2013000134A1 (en) Combination therapy for treating hcv infection